The EPS miss is noise for a pre-commercial biotech; the stock's path hinges on EVERLAST-A Week 28 data (Q3 2026) and EVERLAST-B Week 16 data (Q4 2026). Traders should watch for any early efficacy signals or safety flags from the 28-week readout, which will inform the Phase 3 design and BLA filing timeline. The $1.1B cash runway removes near-term financing risk.
Price Chart
Executive Summary
Oruka Therapeutics reported Q2 2026 results in line with pre-revenue expectations: EPS of -$0.55 (consensus -$0.50) was a 10% miss due to higher R&D spend ($43.3M vs $24.1M YoY), but the stock is driven by pipeline catalysts rather than quarterly profit. The company has $1.1B cash runway through a planned BLA filing for ORKA-001, with multiple upcoming readouts including EVERLAST-A Week 28 data in Q3 2026, EVERLAST-B Week 16 data in Q4 2026, and Phase 3 initiation in 1H 2027.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $41.2M ($0.55/share) vs consensus -$0.50 — a 10% EPS miss due to higher R&D expenses
- Cash, cash equivalents and marketable securities of $1.1B as of June 30, 2026
- EVERLAST-A Week 28 data expected end of Q3 2026; 52-week data for all participants expected December 2026
- EVERLAST-B fully enrolled (187 subjects), Week 16 data expected Q4 2026
- Phase 3 program for ORKA-001 expected to begin 1H 2027
- ORCA-SURGE Week 16 data accelerated to Q1 2027; ORCA-SPLASH Phase 2 in HS initiated
- ORKA-004 (anti-TL1A) to enter clinic in Q4 2026 with planned Phase 2 combo studies in 2027
- Amended IL-23 license with Paragon to include inflammatory bowel disease (IBD)
- R&D expenses $43.3M (up 80% YoY), G&A $6.9M (up 58% YoY), reflecting pipeline expansion
Financial Impact
EPS surprise of -$0.55 vs -$0.50 consensus (-10%), R&D burn accelerating to $43.3M/quarter, cash runway $1.1B sufficient through BLA filing
Risk Factors
- EVERLAST-A Week 28 data could show waning efficacy vs Week 16 (loss of PASI 100 responses)
- EVERLAST-B dose-ranging data may not clearly differentiate from existing IL-23 inhibitors
- Clinical hold or safety signal in any of the three ongoing Phase 2 trials
- Competitive pressure from bimekizumab, guselkumab, and emerging oral therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341704 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access